Phenytoin versus Leviteracetam for Seizure Prophylaxis after brain injury – a meta analysis

Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain inju...

Full description

Saved in:
Bibliographic Details
Published inBMC neurology Vol. 12; no. 1; p. 30
Main Authors Zafar, Syed Nabeel, Khan, Abdul Ahad, Ghauri, Asfar Ayaz, Shamim, Muhammad Shahzad
Format Journal Article
LanguageEnglish
Published London BioMed Central 29.05.2012
BioMed Central Ltd
BMC
Subjects
Adult
Aged
Anti-epileptic drugs
Anticonvulsants
Brain
Brain damage
Brain Injuries - drug therapy
Brain Injuries - epidemiology
Brain injury
Causality
Clinical trials
Comorbidity
Confidence intervals
Convulsants - therapeutic use
Database searching
Drug therapy
Electroencephalography
Female
Humans
Injuries
Internet/Web search services
Levetiracetam
Male
Medicine
Medicine & Public Health
Meta-analysis
Middle Aged
Neurochemistry
Neurology
Neurosurgery
Online searching
Phenytoin
Phenytoin - therapeutic use
Piracetam - analogs & derivatives
Piracetam - therapeutic use
Prevalence
Prevention
Prophylaxis
Research Article
Risk Factors
Seizures
Seizures (Medicine)
Seizures - epidemiology
Seizures - prevention & control
Studies
Treatment Outcome
Karachi Pakistan
Prophylaxis
Anti-epileptic drugs
Phenytoin
Brain injury
Levetiracetam
Meta-analysis
Seizures
Online AccessGet full text
ISSN1471-2377
1471-2377
DOI10.1186/1471-2377-12-30

Cover

Abstract Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury . Methods An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. Results The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate’s Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Conclusions Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
AbstractList Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury. An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury. An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury.BACKGROUNDCurrent standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury.An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures.METHODSAn electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures.The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79).RESULTSThe literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79).Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.CONCLUSIONSLevetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
Doc number: 30 Abstract Background: Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury. Methods: An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. Results: The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Conclusions: Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury. Methods An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. Results The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate's Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Conclusions Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended. Keywords: Levetiracetam, Phenytoin, Meta-analysis, Brain injury, Seizures, Prophylaxis, Anti-epileptic drugs
Abstract Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury. Methods An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. Results The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate’s Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Conclusions Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in patients with brain injury . Methods An electronic search was performed in using Pubmed, Embase, and CENTRAL. We included studies that compared the use of LEV vs. PHY for seizure prophylaxis for brain injured patients (Traumatic brain injury, intracranial hemorrhage, intracranial neoplasms, and craniotomy). Data of all eligible studies was extracted on to a standardized abstraction sheet. Data about baseline population characteristics, type of intervention, study design and outcome was extracted. Our primary outcome was seizures. Results The literature search identified 2489 unduplicated papers. Of these 2456 papers were excluded by reading the abstracts and titles. Another 25 papers were excluded after reading their complete text. We selected 8 papers which comprised of 2 RCTs and 6 observational studies. The pooled estimate’s Odds Ratio 1.12 (95% CI = 0.34, 3.64) demonstrated no superiority of either drug at preventing the occurrence of early seizures. In a subset analysis of studies in which follow up for seizures lasted either 3 or 7 days, the effect estimate remained insignificant with an odds ratio of 0.96 (95% CI = 0.34, 2.76). Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy. The pooled odds ratio was 0.96 (95% CI = 0.24, 3.79). Conclusions Levetiracetam and Phenytoin demonstrate equal efficacy in seizure prevention after brain injury. However, very few randomized controlled trials (RCTs) on the subject were found. Further evidence through a high quality RCT is highly recommended.
ArticleNumber 30
Audience Academic
Author Zafar, Syed Nabeel
Ghauri, Asfar Ayaz
Shamim, Muhammad Shahzad
Khan, Abdul Ahad
AuthorAffiliation 2 Medical College, Aga Khan University, Karachi, Pakistan
1 Department of Surgery, Aga Khan University, Karachi, Pakistan
AuthorAffiliation_xml – name: 2 Medical College, Aga Khan University, Karachi, Pakistan
– name: 1 Department of Surgery, Aga Khan University, Karachi, Pakistan
Author_xml – sequence: 1
  givenname: Syed Nabeel
  surname: Zafar
  fullname: Zafar, Syed Nabeel
  organization: Department of Surgery, Aga Khan University
– sequence: 2
  givenname: Abdul Ahad
  surname: Khan
  fullname: Khan, Abdul Ahad
  organization: Medical College, Aga Khan University
– sequence: 3
  givenname: Asfar Ayaz
  surname: Ghauri
  fullname: Ghauri, Asfar Ayaz
  organization: Medical College, Aga Khan University
– sequence: 4
  givenname: Muhammad Shahzad
  surname: Shamim
  fullname: Shamim, Muhammad Shahzad
  email: shahzad.shamim@aku.edu
  organization: Department of Surgery, Aga Khan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22642837$$D View this record in MEDLINE/PubMed
BookMark eNqNksuO0zAUhiM0iLnAmh2KxIZNZ-z4Fm-QRiMuI1ViJGCJrFPXbl0ldrGTQljxDrwhT4JDh9KORghl4ej4-__j89unxZEP3hTFU4zOMa75BaYCTyoixARXE4IeFCe7ytHe_3FxmtIKISxqih8Vx1XFaVUTcVJ8ulkaP3TB-XJjYupTOTUb15kI2nTQljbE8r1x3_poypsY1suhga8ulWAzU84iZKHzqz4O5c_vP0oo2ywrwUMzJJceFw8tNMk8uV3Pio-vX324ejuZvntzfXU5nWgmWTeRczrTmOuZBCF4zWoJM14TLEDMmZSaSCMpI5ILzgXSlhgLkGt5j5m6qshZcb31nQdYqXV0LcRBBXDqdyHEhYLYOd0YxbSxGFdYCmop57hmFAwzUNnaEgqjF9p69X4Nwxdomp0hRmpMXY25qjFXhStFUJa83ErW_aw1c218F6E5OMfhjndLtQgbRSjiksps8OLWIIbPvUmdal3SpmnAm9Cn3Dh3YQgTntHnd9BV6GPOe0uhGktU_6UWkGd23obcV4-m6pIRihnDnGbq_B4qf3PTOp1fmnW5fiB4tj_obsI_7ykDF1tAx5BSNPY_smN3FNp10LkwJuWaf-hurynlDn5h4n4O90t-AQUM-k0
CitedBy_id crossref_primary_10_1016_j_anrea_2016_09_007
crossref_primary_10_1016_j_jep_2019_112149
crossref_primary_10_1007_s40263_016_0365_0
crossref_primary_10_1097_WNP_0000000000000268
crossref_primary_10_33667_2078_5631_2023_33_13_19
crossref_primary_10_2146_ajhp130439
crossref_primary_10_1097_TA_0000000000001470
crossref_primary_10_3109_02699052_2016_1170882
crossref_primary_10_1007_s12028_022_01475_6
crossref_primary_10_1007_s40263_013_0094_6
crossref_primary_10_1016_j_wneu_2018_11_076
crossref_primary_10_1371_journal_pone_0265932
crossref_primary_10_1016_j_prro_2015_11_004
crossref_primary_10_1080_02699052_2023_2184495
crossref_primary_10_1212_CON_0000000000001039
crossref_primary_10_1016_j_ccc_2016_08_008
crossref_primary_10_1097_TA_0b013e3182826e84
crossref_primary_10_1007_s00113_017_0344_z
crossref_primary_10_1080_02688697_2018_1464118
crossref_primary_10_1016_j_inat_2021_101394
crossref_primary_10_1016_j_neuchi_2016_10_013
crossref_primary_10_1097_MD_0000000000013247
crossref_primary_10_1016_j_pediatrneurol_2021_10_009
crossref_primary_10_1371_journal_pone_0273998
crossref_primary_10_1007_s13760_024_02474_4
crossref_primary_10_1016_j_accpm_2017_12_001
crossref_primary_10_5698_1535_7597_14_1_24
crossref_primary_10_5863_1551_6776_25_3_241
crossref_primary_10_1097_ANA_0000000000000225
crossref_primary_10_3390_ph15070838
crossref_primary_10_1016_j_yebeh_2016_07_012
crossref_primary_10_1111_ane_13131
crossref_primary_10_1186_s13643_017_0629_x
crossref_primary_10_13004_kjnt_2020_16_e43
crossref_primary_10_1227_NEU_0000000000001445
crossref_primary_10_1016_j_jeurea_2017_04_007
crossref_primary_10_1371_journal_pone_0198676
crossref_primary_10_3389_fphar_2022_1001363
crossref_primary_10_3389_fneur_2016_00032
crossref_primary_10_1007_s11096_017_0507_6
crossref_primary_10_1016_j_seizure_2016_11_017
crossref_primary_10_3390_ijms15010309
crossref_primary_10_1016_j_pmr_2016_12_004
crossref_primary_10_5005_jp_journals_10071_24235
crossref_primary_10_1093_toxsci_kfy218
crossref_primary_10_1002_epi4_12049
crossref_primary_10_1080_14737175_2025_2469041
crossref_primary_10_1097_MJT_0b013e31828fdaed
crossref_primary_10_1177_1460408615619435
crossref_primary_10_1007_s40140_013_0012_y
crossref_primary_10_1586_ecp_13_12
crossref_primary_10_1007_s12028_013_9951_x
crossref_primary_10_1002_phar_2797
crossref_primary_10_1097_MS9_0000000000001291
crossref_primary_10_3390_biomedicines12040781
crossref_primary_10_1097_PCC_0000000000000588
crossref_primary_10_1111_bcp_12926
crossref_primary_10_1007_s00415_019_09541_4
crossref_primary_10_1177_1060028014549013
crossref_primary_10_1007_s12028_021_01296_z
crossref_primary_10_1186_s13054_018_2066_1
crossref_primary_10_1016_j_jocn_2022_07_014
crossref_primary_10_3390_medicines11050010
crossref_primary_10_1007_s11940_013_0275_0
crossref_primary_10_1097_ANA_0000000000000206
Cites_doi 10.1111/j.1528-1167.2006.00586.x
10.1136/bmj.315.7109.629
10.1016/0090-3019(81)90227-5
10.1097/TA.0b013e318224d307
10.3171/jns.1983.58.5.0672
10.1097/WNF.0b013e31806ad6cb
10.1001/jama.283.15.2008
10.1212/WNL.40.1.158
10.1212/01.wnl.0000324624.52935.46
10.3171/FOC.2008.25.10.E3
10.1186/1472-6963-3-23
10.1161/STROKEAHA.109.559948
10.1007/BF01665108
10.1007/s12028-007-0042-8
10.1136/bmj.327.7414.557
10.1002/cpt1979264445
10.1007/s11060-004-6912-4
10.1212/01.WNL.0000031432.05543.14
10.1016/j.seizure.2009.09.003
10.1007/s12028-009-9304-y
10.1016/j.clineuro.2005.09.001
10.1016/j.wneu.2010.09.002
10.1212/WNL.55.9.1315
10.1007/s11060-008-9781-4
10.1007/s12028-010-9341-6
10.1046/j.1528-1157.2002.24801.x
10.1001/archneur.1995.00540310091021
10.1212/01.wnl.0000168903.09277.8f
10.1002/med.2610030403
10.1007/BF00165714
10.1227/00006123-198509000-00021
10.1097/ACO.0b013e32833e14f2
10.1046/j.1535-7597.2002.00038.x
10.1056/NEJM199008233230801
10.1212/WNL.46.4.985
10.1017/S0317167100053361
10.1002/14651858.CD000173
10.1002/14651858.CD004424.pub2
ContentType Journal Article
Copyright Zafar et al.; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
COPYRIGHT 2012 BioMed Central Ltd.
2012 Zafar et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2012 Zafar et al.; licensee BioMed Central Ltd. 2012 Zafar et al.; licensee BioMed Central Ltd.
Copyright_xml – notice: Zafar et al.; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: COPYRIGHT 2012 BioMed Central Ltd.
– notice: 2012 Zafar et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2012 Zafar et al.; licensee BioMed Central Ltd. 2012 Zafar et al.; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1186/1471-2377-12-30
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ (selected full-text)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2377
EndPage 30
ExternalDocumentID oai_doaj_org_article_5cef1121974f4661854ae5ea2f8f34a2
10.1186/1471-2377-12-30
PMC3406949
2722051911
A534155164
22642837
10_1186_1471_2377_12_30
Genre Meta-Analysis
Comparative Study
Review
Journal Article
GeographicLocations Karachi Pakistan
GeographicLocations_xml – name: Karachi Pakistan
GroupedDBID ---
0R~
23N
2VQ
2WC
4.4
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IGS
IHR
INH
INR
IPNFZ
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
123
ADTOC
C1A
H13
UNPAY
ID FETCH-LOGICAL-c595t-9d4bc16cb9a7768589ab68317a7d599c39e94539676670cf3efaa9e95995e8223
IEDL.DBID UNPAY
ISSN 1471-2377
IngestDate Wed Aug 27 01:29:18 EDT 2025
Wed Aug 20 00:18:45 EDT 2025
Tue Sep 30 15:43:11 EDT 2025
Sun Aug 24 03:07:51 EDT 2025
Fri Jul 25 07:12:29 EDT 2025
Tue Jun 17 22:05:26 EDT 2025
Mon Jul 21 10:57:42 EDT 2025
Mon Jul 21 05:58:42 EDT 2025
Thu Apr 24 23:04:23 EDT 2025
Wed Oct 01 03:13:47 EDT 2025
Sat Sep 06 07:22:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Prophylaxis
Anti-epileptic drugs
Phenytoin
Brain injury
Levetiracetam
Meta-analysis
Seizures
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c595t-9d4bc16cb9a7768589ab68317a7d599c39e94539676670cf3efaa9e95995e8223
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://bmcneurol.biomedcentral.com/counter/pdf/10.1186/1471-2377-12-30
PMID 22642837
PQID 1030081908
PQPubID 44772
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_5cef1121974f4661854ae5ea2f8f34a2
unpaywall_primary_10_1186_1471_2377_12_30
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3406949
proquest_miscellaneous_1030350136
proquest_journals_1030081908
gale_infotracmisc_A534155164
gale_infotracacademiconefile_A534155164
pubmed_primary_22642837
crossref_primary_10_1186_1471_2377_12_30
crossref_citationtrail_10_1186_1471_2377_12_30
springer_journals_10_1186_1471_2377_12_30
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-05-29
PublicationDateYYYYMMDD 2012-05-29
PublicationDate_xml – month: 05
  year: 2012
  text: 2012-05-29
  day: 29
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC neurology
PublicationTitleAbbrev BMC Neurol
PublicationTitleAlternate BMC Neurol
PublicationYear 2012
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References Stroup, Berlin, Morton, Olkin, Williamson, Rennie, Moher, Becker, Sipe, Thacker (CR9) 2000; 283
De Santis, Villani, Sinisi, Stocchetti, Perucca (CR19) 2002; 43
Butzkueven, Evans, Pitman, Leopold, Jolley, Kaye, Kilpatrick, Davis (CR22) 2000; 55
Temkin, Dikmen, Wilensky, Keihm, Chabal, Winn (CR2) 1990; 323
Sahin, Comert, Akin, Ayalp, Karsidag (CR4) 2008; 31
Siomin, Angelov, Li, Vogelbaum (CR21) 2005; 74
Moots, Maciunas, Eisert, Parker, Laporte, Abou-Khalil (CR35) 1995; 52
Agrawal, Timothy, Pandit, Manju (CR31) 2006; 108
Glantz, Cole, Friedberg, Lathi, Choy, Furie, Akerley, Wahlberg, Lekos, Louis (CR36) 1996; 46
Hildebrand, Lecaille, Perennes, Delattre (CR20) 2005; 65
CR32
Szaflarski, Sangha, Lindsell, Shutter (CR8) 2010; 12
Klimek, Dammers (CR1) 2010; 23
Naidech, Garg, Liebling, Levasseur, Macken, Schuele, Batjer (CR16) 2009; 40
North, Penhall, Hanieh, Frewin, Taylor (CR24) 1983; 58
Shah, Husain (CR38) 2009; 18
Lim, Tarapore, Chang, Burt, Chakalian, Barbaro, Chang, Lamborn, McDermott (CR13) 2009; 93
Ramael, Daoust, Otoul, Toublanc, Troenaru, Lu, Stockis (CR5) 2006; 47
Jones, Wimbish, McIntosh (CR3) 1983; 3
Deutschman, Haines (CR23) 1985; 17
Foy, Copeland, Shaw (CR25) 1981; 57
Byrne, Cascino, Posner (CR27) 1983; 1
Szaflarski, Meckler, Szaflarski, Shutter, Privitera, Yates (CR17) 2007; 7
Ketz (CR26) 1974; 16
Mahaley, Dudka (CR33) 1981; 16
Jones, Puccio, Harshman, Falcione, Benedict, Jankowitz, Stippler, Fischer, Sauber-Schatz, Fabio (CR7) 2008; 25
CR28
Milligan, Hurwitz, Bromfield (CR12) 2008; 71
Temkin (CR29) 2002; 2
Chang, Lowenstein (CR30) 2003; 60
Taylor, Heinrichs, Janzen, Ehtisham (CR14) 2011; 15
Murphy-Human, Welch, Zipfel, Diringer, Dhar (CR15) 2011; 75
Forsyth, Weaver, Fulton, Brasher, Sutherland, Stewart, Hagen, Barnes, Cairncross, DeAngelis (CR37) 2003; 30
Brouwers, Chambers, Perry (CR18) 2003; 3
Cotton, Kao, Kozar, Holcomb (CR6) 2011; 71
Egger, Smith, Schneider, Minder (CR11) 1997; 315
Hagen, Cirrincione, Thaler, DeAngelis (CR34) 1990; 40
Higgins, Thompson, Deeks, Altman (CR10) 2003; 327
Allen, Ludden, Burrow, Clementi, Stavchansky (CR39) 1979; 26
JB North (590_CR24) 1983; 58
A Agrawal (590_CR31) 2006; 108
PL Moots (590_CR35) 1995; 52
PM Foy (590_CR25) 1981; 57
590_CR32
TA Milligan (590_CR12) 2008; 71
BS Chang (590_CR30) 2003; 60
KE Jones (590_CR7) 2008; 25
M Egger (590_CR11) 1997; 315
H Butzkueven (590_CR22) 2000; 55
MC Brouwers (590_CR18) 2003; 3
DA Lim (590_CR13) 2009; 93
V Siomin (590_CR21) 2005; 74
JP Higgins (590_CR10) 2003; 327
S Sahin (590_CR4) 2008; 31
MJ Glantz (590_CR36) 1996; 46
CS Deutschman (590_CR23) 1985; 17
NR Temkin (590_CR29) 2002; 2
AM Naidech (590_CR16) 2009; 40
J Hildebrand (590_CR20) 2005; 65
JP Szaflarski (590_CR17) 2007; 7
PA Forsyth (590_CR37) 2003; 30
D Shah (590_CR38) 2009; 18
GL Jones (590_CR3) 1983; 3
NR Temkin (590_CR2) 1990; 323
A De Santis (590_CR19) 2002; 43
MS Mahaley (590_CR33) 1981; 16
JP Allen (590_CR39) 1979; 26
J Szaflarski (590_CR8) 2010; 12
DF Stroup (590_CR9) 2000; 283
590_CR28
NA Hagen (590_CR34) 1990; 40
T Murphy-Human (590_CR15) 2011; 75
S Ramael (590_CR5) 2006; 47
E Ketz (590_CR26) 1974; 16
TN Byrne (590_CR27) 1983; 1
BA Cotton (590_CR6) 2011; 71
M Klimek (590_CR1) 2010; 23
S Taylor (590_CR14) 2011; 15
References_xml – volume: 47
  start-page: 1128
  issue: 7
  year: 2006
  end-page: 1135
  ident: CR5
  article-title: Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2006.00586.x
– volume: 315
  start-page: 629
  issue: 7109
  year: 1997
  end-page: 634
  ident: CR11
  article-title: Bias in meta-analysis detected by a simple, graphical test
  publication-title: BMJ
  doi: 10.1136/bmj.315.7109.629
– volume: 16
  start-page: 399
  issue: 6
  year: 1981
  end-page: 401
  ident: CR33
  article-title: The role of anticonvulsant medications in the management of patients with anaplastic gliomas
  publication-title: Surg Neurol
  doi: 10.1016/0090-3019(81)90227-5
– volume: 71
  start-page: 375
  issue: 2
  year: 2011
  end-page: 379
  ident: CR6
  article-title: Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis
  publication-title: J Trauma
  doi: 10.1097/TA.0b013e318224d307
– volume: 58
  start-page: 672
  issue: 5
  year: 1983
  end-page: 677
  ident: CR24
  article-title: Phenytoin and postoperative epilepsy. A double-blind study
  publication-title: J Neurosurg
  doi: 10.3171/jns.1983.58.5.0672
– volume: 31
  start-page: 93
  issue: 2
  year: 2008
  end-page: 96
  ident: CR4
  article-title: Cutaneous drug eruptions by current antiepileptics: case reports and alternative treatment options
  publication-title: Clin Neuropharmacol
  doi: 10.1097/WNF.0b013e31806ad6cb
– volume: 283
  start-page: 2008
  issue: 15
  year: 2000
  end-page: 2012
  ident: CR9
  article-title: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group
  publication-title: JAMA
  doi: 10.1001/jama.283.15.2008
– volume: 40
  start-page: 158
  issue: 1
  year: 1990
  end-page: 160
  ident: CR34
  article-title: The role of radiation therapy following resection of single brain metastasis from melanoma
  publication-title: Neurology
  doi: 10.1212/WNL.40.1.158
– volume: 71
  start-page: 665
  issue: 9
  year: 2008
  end-page: 669
  ident: CR12
  article-title: Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000324624.52935.46
– volume: 25
  start-page: E3
  issue: 4
  year: 2008
  ident: CR7
  article-title: Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury
  publication-title: Neurosurg Focus
  doi: 10.3171/FOC.2008.25.10.E3
– volume: 3
  start-page: 23
  issue: 1
  year: 2003
  ident: CR18
  article-title: Can surveying practitioners about their practices help identify priority clinical practice guideline topics?
  publication-title: BMC Health Serv Res
  doi: 10.1186/1472-6963-3-23
– volume: 40
  start-page: 3810
  issue: 12
  year: 2009
  end-page: 3815
  ident: CR16
  article-title: Anticonvulsant use and outcomes after intracerebral hemorrhage
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.109.559948
– volume: 57
  start-page: 15
  issue: 1–2
  year: 1981
  end-page: 22
  ident: CR25
  article-title: The natural history of postoperative seizures
  publication-title: Acta Neurochir (Wien)
  doi: 10.1007/BF01665108
– volume: 16
  start-page: 254
  year: 1974
  end-page: 256
  ident: CR26
  article-title: Brain tumours and epilepsy
  publication-title: Handbook of Clinical Neurology
– volume: 7
  start-page: 140
  issue: 2
  year: 2007
  end-page: 147
  ident: CR17
  article-title: Levetiracetam use in critically ill patients
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-007-0042-8
– volume: 327
  start-page: 557
  issue: 7414
  year: 2003
  end-page: 560
  ident: CR10
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
– volume: 26
  start-page: 445
  issue: 4
  year: 1979
  end-page: 448
  ident: CR39
  article-title: Phenytoin cumulation kinetics
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt1979264445
– volume: 74
  start-page: 211
  issue: 2
  year: 2005
  end-page: 215
  ident: CR21
  article-title: Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors
  publication-title: J Neurooncol
  doi: 10.1007/s11060-004-6912-4
– volume: 60
  start-page: 10
  issue: 1
  year: 2003
  end-page: 16
  ident: CR30
  article-title: Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000031432.05543.14
– volume: 18
  start-page: 676
  issue: 10
  year: 2009
  end-page: 679
  ident: CR38
  article-title: Utility of levetiracetam in patients with subarachnoid hemorrhage
  publication-title: Seizure
  doi: 10.1016/j.seizure.2009.09.003
– volume: 12
  start-page: 165
  issue: 2
  year: 2010
  end-page: 172
  ident: CR8
  article-title: Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis
  publication-title: Neurocritical Care
  doi: 10.1007/s12028-009-9304-y
– volume: 108
  start-page: 433
  issue: 5
  year: 2006
  end-page: 439
  ident: CR31
  article-title: Post-traumatic epilepsy: an overview
  publication-title: Clin Neurol Neurosurg
  doi: 10.1016/j.clineuro.2005.09.001
– volume: 75
  start-page: 269
  issue: 2
  year: 2011
  end-page: 274
  ident: CR15
  article-title: Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2010.09.002
– volume: 55
  start-page: 1315
  issue: 9
  year: 2000
  end-page: 1320
  ident: CR22
  article-title: Onset seizures independently predict poor outcome after subarachnoid hemorrhage
  publication-title: Neurology
  doi: 10.1212/WNL.55.9.1315
– volume: 93
  start-page: 349
  issue: 3
  year: 2009
  end-page: 354
  ident: CR13
  article-title: Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study
  publication-title: J Neurooncol
  doi: 10.1007/s11060-008-9781-4
– volume: 15
  start-page: 80
  issue: 1
  year: 2011
  end-page: 84
  ident: CR14
  article-title: Levetiracetam is Associated with Improved Cognitive Outcome for Patients with Intracranial Hemorrhage
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-010-9341-6
– volume: 43
  start-page: 175
  year: 2002
  end-page: 182
  ident: CR19
  article-title: Add-on Phenytoin Fails to Prevent Early Seizures after Surgery for Supratentorial Brain Tumors: A Randomized Controlled Study
  publication-title: Epilepsia
  doi: 10.1046/j.1528-1157.2002.24801.x
– volume: 52
  start-page: 717
  issue: 7
  year: 1995
  end-page: 724
  ident: CR35
  article-title: The course of seizure disorders in patients with malignant gliomas
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1995.00540310091021
– volume: 65
  start-page: 212
  issue: 2
  year: 2005
  end-page: 215
  ident: CR20
  article-title: Epileptic seizures during follow-up of patients treated for primary brain tumors
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000168903.09277.8f
– volume: 3
  start-page: 383
  issue: 4
  year: 1983
  end-page: 434
  ident: CR3
  article-title: Phenytoin: basic and clinical pharmacology
  publication-title: Med Res Rev
  doi: 10.1002/med.2610030403
– volume: 1
  start-page: 313
  issue: 4
  year: 1983
  end-page: 317
  ident: CR27
  article-title: Brain metastasis from melanoma
  publication-title: J Neurooncol
  doi: 10.1007/BF00165714
– ident: CR32
– volume: 17
  start-page: 510
  issue: 3
  year: 1985
  end-page: 517
  ident: CR23
  article-title: Anticonvulsant prophylaxis in neurological surgery
  publication-title: Neurosurgery
  doi: 10.1227/00006123-198509000-00021
– volume: 23
  start-page: 564
  issue: 5
  year: 2010
  end-page: 567
  ident: CR1
  article-title: Antiepileptic drug therapy in the perioperative course of neurosurgical patients
  publication-title: Curr Opin Anaesthesiol
  doi: 10.1097/ACO.0b013e32833e14f2
– ident: CR28
– volume: 2
  start-page: 105
  issue: 4
  year: 2002
  end-page: 107
  ident: CR29
  article-title: Prophylactic Anticonvulsants after Neurosurgery
  publication-title: Epilepsy Curr
  doi: 10.1046/j.1535-7597.2002.00038.x
– volume: 30
  start-page: 106
  issue: 2
  year: 2003
  end-page: 112
  ident: CR37
  article-title: Prophylactic anticonvulsants in patients with brain tumour
  publication-title: Can J Neurol Sci
– volume: 323
  start-page: 497
  issue: 8
  year: 1990
  end-page: 502
  ident: CR2
  article-title: A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199008233230801
– volume: 46
  start-page: 985
  issue: 4
  year: 1996
  end-page: 991
  ident: CR36
  article-title: A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors
  publication-title: Neurology
  doi: 10.1212/WNL.46.4.985
– volume: 47
  start-page: 1128
  issue: 7
  year: 2006
  ident: 590_CR5
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2006.00586.x
– volume: 108
  start-page: 433
  issue: 5
  year: 2006
  ident: 590_CR31
  publication-title: Clin Neurol Neurosurg
  doi: 10.1016/j.clineuro.2005.09.001
– volume: 16
  start-page: 399
  issue: 6
  year: 1981
  ident: 590_CR33
  publication-title: Surg Neurol
  doi: 10.1016/0090-3019(81)90227-5
– volume: 323
  start-page: 497
  issue: 8
  year: 1990
  ident: 590_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199008233230801
– volume: 23
  start-page: 564
  issue: 5
  year: 2010
  ident: 590_CR1
  publication-title: Curr Opin Anaesthesiol
  doi: 10.1097/ACO.0b013e32833e14f2
– volume: 18
  start-page: 676
  issue: 10
  year: 2009
  ident: 590_CR38
  publication-title: Seizure
  doi: 10.1016/j.seizure.2009.09.003
– volume: 93
  start-page: 349
  issue: 3
  year: 2009
  ident: 590_CR13
  publication-title: J Neurooncol
  doi: 10.1007/s11060-008-9781-4
– volume: 3
  start-page: 23
  issue: 1
  year: 2003
  ident: 590_CR18
  publication-title: BMC Health Serv Res
  doi: 10.1186/1472-6963-3-23
– volume: 60
  start-page: 10
  issue: 1
  year: 2003
  ident: 590_CR30
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000031432.05543.14
– volume: 75
  start-page: 269
  issue: 2
  year: 2011
  ident: 590_CR15
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2010.09.002
– volume: 17
  start-page: 510
  issue: 3
  year: 1985
  ident: 590_CR23
  publication-title: Neurosurgery
  doi: 10.1227/00006123-198509000-00021
– volume: 46
  start-page: 985
  issue: 4
  year: 1996
  ident: 590_CR36
  publication-title: Neurology
  doi: 10.1212/WNL.46.4.985
– volume: 31
  start-page: 93
  issue: 2
  year: 2008
  ident: 590_CR4
  publication-title: Clin Neuropharmacol
  doi: 10.1097/WNF.0b013e31806ad6cb
– volume: 30
  start-page: 106
  issue: 2
  year: 2003
  ident: 590_CR37
  publication-title: Can J Neurol Sci
  doi: 10.1017/S0317167100053361
– ident: 590_CR28
  doi: 10.1002/14651858.CD000173
– volume: 55
  start-page: 1315
  issue: 9
  year: 2000
  ident: 590_CR22
  publication-title: Neurology
  doi: 10.1212/WNL.55.9.1315
– volume: 327
  start-page: 557
  issue: 7414
  year: 2003
  ident: 590_CR10
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
– volume: 40
  start-page: 3810
  issue: 12
  year: 2009
  ident: 590_CR16
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.109.559948
– volume: 57
  start-page: 15
  issue: 1–2
  year: 1981
  ident: 590_CR25
  publication-title: Acta Neurochir (Wien)
  doi: 10.1007/BF01665108
– volume: 7
  start-page: 140
  issue: 2
  year: 2007
  ident: 590_CR17
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-007-0042-8
– volume: 3
  start-page: 383
  issue: 4
  year: 1983
  ident: 590_CR3
  publication-title: Med Res Rev
  doi: 10.1002/med.2610030403
– volume: 283
  start-page: 2008
  issue: 15
  year: 2000
  ident: 590_CR9
  publication-title: JAMA
  doi: 10.1001/jama.283.15.2008
– volume: 58
  start-page: 672
  issue: 5
  year: 1983
  ident: 590_CR24
  publication-title: J Neurosurg
  doi: 10.3171/jns.1983.58.5.0672
– volume: 65
  start-page: 212
  issue: 2
  year: 2005
  ident: 590_CR20
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000168903.09277.8f
– volume: 26
  start-page: 445
  issue: 4
  year: 1979
  ident: 590_CR39
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt1979264445
– volume: 71
  start-page: 665
  issue: 9
  year: 2008
  ident: 590_CR12
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000324624.52935.46
– volume: 43
  start-page: 175
  year: 2002
  ident: 590_CR19
  publication-title: Epilepsia
  doi: 10.1046/j.1528-1157.2002.24801.x
– volume: 315
  start-page: 629
  issue: 7109
  year: 1997
  ident: 590_CR11
  publication-title: BMJ
  doi: 10.1136/bmj.315.7109.629
– volume: 52
  start-page: 717
  issue: 7
  year: 1995
  ident: 590_CR35
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1995.00540310091021
– volume: 71
  start-page: 375
  issue: 2
  year: 2011
  ident: 590_CR6
  publication-title: J Trauma
  doi: 10.1097/TA.0b013e318224d307
– volume: 1
  start-page: 313
  issue: 4
  year: 1983
  ident: 590_CR27
  publication-title: J Neurooncol
  doi: 10.1007/BF00165714
– volume: 25
  start-page: E3
  issue: 4
  year: 2008
  ident: 590_CR7
  publication-title: Neurosurg Focus
  doi: 10.3171/FOC.2008.25.10.E3
– volume: 12
  start-page: 165
  issue: 2
  year: 2010
  ident: 590_CR8
  publication-title: Neurocritical Care
  doi: 10.1007/s12028-009-9304-y
– volume: 2
  start-page: 105
  issue: 4
  year: 2002
  ident: 590_CR29
  publication-title: Epilepsy Curr
  doi: 10.1046/j.1535-7597.2002.00038.x
– volume: 40
  start-page: 158
  issue: 1
  year: 1990
  ident: 590_CR34
  publication-title: Neurology
  doi: 10.1212/WNL.40.1.158
– volume: 74
  start-page: 211
  issue: 2
  year: 2005
  ident: 590_CR21
  publication-title: J Neurooncol
  doi: 10.1007/s11060-004-6912-4
– volume: 15
  start-page: 80
  issue: 1
  year: 2011
  ident: 590_CR14
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-010-9341-6
– volume: 16
  start-page: 254
  year: 1974
  ident: 590_CR26
  publication-title: Handbook of Clinical Neurology
– ident: 590_CR32
  doi: 10.1002/14651858.CD004424.pub2
SSID ssj0017841
Score 2.2649586
SecondaryResourceType review_article
Snippet Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam...
Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is...
Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam...
Doc number: 30 Abstract Background: Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a...
Abstract Background Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 30
SubjectTerms Adult
Aged
Anti-epileptic drugs
Anticonvulsants
Brain
Brain damage
Brain Injuries - drug therapy
Brain Injuries - epidemiology
Brain injury
Causality
Clinical trials
Comorbidity
Confidence intervals
Convulsants - therapeutic use
Database searching
Drug therapy
Electroencephalography
Female
Humans
Injuries
Internet/Web search services
Levetiracetam
Male
Medicine
Medicine & Public Health
Meta-analysis
Middle Aged
Neurochemistry
Neurology
Neurosurgery
Online searching
Phenytoin
Phenytoin - therapeutic use
Piracetam - analogs & derivatives
Piracetam - therapeutic use
Prevalence
Prevention
Prophylaxis
Research Article
Risk Factors
Seizures
Seizures (Medicine)
Seizures - epidemiology
Seizures - prevention & control
Studies
Treatment Outcome
SummonAdditionalLinks – databaseName: DOAJ (selected full-text)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDzwOiDehBRkJCXoIzcbvY0FUFaKoElTqBVmO46ipttlqdyNaTvwH_iG_hBknG21AVS9c_ZDsmbHns8bzDSGvypIrx0WVSq7hgcJZlhrlXZqr0rMgdKg85jsffJb7R_zjsTheK_WFf8I6euBOcDvChwowwQRwb8XBmWjBXRDB5ZWuGHfx9gU3tnpM9fEDjKbFvCI1SXOmVE_qM9FyZ2iLdH3ZyB9F2v5_L-c17_T3z8khfHqH3Gqbc3f53U2nax5q7x6520NLuttt6T65EZoH5OZBHzx_SL4dnoTmcjmrG4p_MdoF_QReETOQfVi6MwrwlX4J9Y92HujhfAbyn7qLekFjGXFaYC0JWjenoAT6--cv6ugZTKOuZzV5RI72Pnx9v5_21RVSL4xYpqbkhZ9IXxinFLLQG1dIDXDCqVIY45kJhgtmpJJSZb5ioXIO2pChLACsYI_JRjNrwlNCCy0qOMneM-24yUpdlIYjWZkKMgf0npC3Kxlb31OPYwWMqY1PEC0tKsWiUuwktyxLyJthwnnHunH10HeotGEY0mXHBjAi2xuRvc6IEvIaVW7xUMPCvOtzE2B7SI9ldwXjMaTIE7I1GgmH0Y-7V0Zj-8tgYbGSW0ReOiEvh26ciR_cmjBruzEY42UyIU86Gxu2hLnOSFKUEDWyvtGexz1NfRKpwllMbAYFbK_sdH1ZVwh0ezDk64T_7H8If5PcBhSa45eM3GyRjeW8Dc8B6S2LF_FQ_wF6QUn-
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bi9QwFA66gpcH8W51lQiC7kN3p82teZJVXBZxZUEXBnwIaZq6I7PtONNB11_vOZlMnSqrr00CybmnJ-c7hDyvKq4sF3UqeQEXFM5GqVbOprmqHPOi8LXDeuejD_LwhL8bi3H84baIzyrXNjEY6qp1-I98D9thBfdVvJp9S7FrFGZXYwuNy-RKBqEKSrUa9xeuDHNqEc4nK-ReBoY4zZlSAahvNPBEAbD_b7O84Zf-fDPZJ05vkGvLZmbPv9vpdMM3HdwiN2NQSfdXUnCbXPLNHXL1KKbN75LPx6e-Oe_aSUPxFcZyQd-DP8TaY-c7e0YhcKUf_eTncu7p8bwFyk_tj8mChgbitMQuEnTSfAXy05RaegaLqI1oJvfIycHbT28O09hVIXVCiy7VFS9dJl2prVKIPq9tKQsII6yqhNaOaa-5YFoqKdXI1czX1sI3RCbzEE6w-2SraRv_kNCyEDVosHOssFyPqqKsNEeQMuVlDlF7QnbXFDYuQo5j54upCVePQhpkiUGWmCw3bJSQl_2C2Qpt4-Kpr5Fl_TSEyQ4f2vkXE7XOCOdrCCgzuDTVHCKRQnDrhbd5XdSM2zwhL5DhBpUZNuZsrEmA4yEsltkXjIdUIk_I9mAmKKEbDq9FxkQjsDC_RTYhz_phXIkP2xrfLldzMLfLZEIerCSsPxLWOCM4UULUQPYGZx6ONJPTABHOQkEzMGBnLaWb27qAoDu9GP-P-I_-fdzH5DrElTk-ssj1Ntnq5kv_BGK3rnwaFPQXq0g-Aw
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLbQkLg8IO4EBjISEuwho43vDwgNxDQhinig0iQeLMdxWFCXjjYVK7-ec9w0a2AVr7Et2T7fyfmsY3-HkBdFwZXjokwl13BA4WyQGuVdmqnCsyB0KD2-dx59lkdj_vFYHF-UA2o3cH7p0Q7rSY1nk_3zn8u34PBvosNr-XoIP9g0Y0pFAT44v1-FsJQhxEf8IqWACbZW2-eSQSgKnCEXx4LoGxEqCvn_-7veiFd_36XsEqo3yfVFfeaWv9xkshGzDm-TWy3ZpAcrdNwhV0J9l1wbten0e-Tbl5NQL5tpVVO8nbGY008QJ_FNsg-NO6VAaOk8VL8Xs0BhTmCRiTuv5jQWFqc5VpegVf0DzEJT6ugpDKKuVTm5T8aHH76-P0rbagupF0Y0qSl47ofS58Yphar0xuVSA71wqhDGeGaC4YIZqaRUA1-yUDoH31CxLADNYA_ITj2twyNCcy1K8GzvmXbcDAqdF4ajeJkKMgM2n5D99Q5b30qRY0WMiY1HEi0tWseidewws2yQkFfdgLOVCsf2ru_QZF03lM-OH6az77b1Rit8KIFoDuEwVXJgKFpwF0RwWalLxl2WkJdocIuwg4l5175VgOWhXJY9EIzHFCNPyG6vJzin7zevIWPX2LZY2S0yMZ2Q510zjsQLb3WYLlZ9MOfLZEIerhDWLWkN1ISoHvZ6a-631NVJlA5n8aEzGGBvjdLNaW3Z0L0Oxv_b_Mdb5_qE3ACqmeG9i8zskp1mtghPgc41-bPopn8AzmZAgQ
  priority: 102
  providerName: Scholars Portal
– databaseName: SpringerOpen Free (Free internet resource, activated by CARLI)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9RAFB6kgpcH8W60ygiC9iG6ydwf62IpYqWghb7IMJlMaGSbLbsJWp_8D_5Df4nnzGbDRi3i61xC5lxmvuGc8w0hz8qSK8dFlUqu4YLC2SQ1yrs0V6VnQehQeax3Pngv94_422Nx3JMkYS3MZvw-0_JVBptnmjOlIrke3M0vC9h1MXdvKqdDuACDZz1vz18mjY6cyMz_5_67cQD9nhw5REivk6tdc-bOv7jZbOMQ2rtJbvToke6u1H2LXArNbXLloI-P3yGfDk9Cc97O64ZiukW3pO_g4MMiYx9ad0oBodIPof7WLQI9XMxBxDP3tV7S-FI4LfC5CFo3n0HO9Of3H9TRU5hGXU9ccpcc7b35ON1P-wcUUi-MaFNT8sJn0hfGKYVE88YVUgNicKoUxnhmguGCGamkVBNfsVA5B21IQhYAObB7ZKuZN-EBoYUWFTir90w7bialLkrDkY9MBZkDQE_Iy7WMre_ZxfGRi5mNtwwtLSrFolJslls2SciLYcLZiljj4qGvUWnDMGTEjg1gKLZ3MCt8qAA7ZnA_qjiADi24CyK4vNIV4y5PyHNUuUW_hR_zri8_gOUhA5bdFYzHqCFPyPZoJPibH3evjcb2_r60-FhbBFc6IU-HbpyJOWxNmHerMRjGZTIh91c2NiwJy5mRhyghamR9ozWPe5r6JLKBs1i7DArYWdvp5m9dINCdwZD_JfyH__HdR-Qa4Mkckytys0222kUXHgNma4sn0V9_ATONNv8
  priority: 102
  providerName: Springer Nature
Title Phenytoin versus Leviteracetam for Seizure Prophylaxis after brain injury – a meta analysis
URI https://link.springer.com/article/10.1186/1471-2377-12-30
https://www.ncbi.nlm.nih.gov/pubmed/22642837
https://www.proquest.com/docview/1030081908
https://www.proquest.com/docview/1030350136
https://pubmed.ncbi.nlm.nih.gov/PMC3406949
https://bmcneurol.biomedcentral.com/counter/pdf/10.1186/1471-2377-12-30
https://doaj.org/article/5cef1121974f4661854ae5ea2f8f34a2
UnpaywallVersion publishedVersion
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central Open Access Free
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: M48
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2377
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017841
  issn: 1471-2377
  databaseCode: C6C
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELaWVuJx4P0ILJWRkGAP6bax48exW-2yQrSqgErlgCzHcWghTas2Eeye-A_8Q34JtpNG7cIKIXGp1HgsxeOZ8Uw88w0Az-MYU4nDxCeYmQAFo47PqZJ-QGOFdMh0omy982BITsf49SSc7IFXm1qYaK4ckGPa3i4_T8vqBts9Qa8Ol3FSKjsjh11jXP0AUerA90zs3iT2pqkBmuPhqPfB1RZVFBWwzx9m7ZxJDrr_dwO9dUJdzJ6sr1BvgGtFtpRnX2Wabp1SJ7fAdLO-MjnlS7vIo7Y6vwD9-B8YcBvcrDxZ2CtF7w7Y09ldcHVQ3dXfAx9HU52d5YtZBm3qR7GGb8whbAuelc7lHBpvGb7Ts_NipeFotTDbncpvszV0XcthZFtXwFn22ew5_Pn9B5RwbqZBWYGo3Afjk-P3_VO_aubgq5CHuc9jHKkuURGXlFrQey4jwoz3Imkccq4Q1xyHiBNKCO2oBOlESvPMAqJp48WgB6CRLTL9CMCIhYkxHEohJjHvxCyKObbYaFSTwAQLHmhvtlOoCuncNtxIhYt4GBGWacIyTXQDgToeeFlPWJYgH5eTHln5qMksOrd7sFh9EpWyi1DpxPixXROrJdg4QCzEUodaBglLEJaBB15Y6RLWhpgXU7IqhTDLs2hcohci7G4wsQf2dyiN7qvd4Y18isr2rIVtHOccPeaBZ_WwnWnz6TK9KEoae6WMiAceluJcL8mWVltMJA_QHUHfWfPuSDabOmRy5OqozQYcbFRi-7UuYehBrTN_Y_7jf6B9Aq4b3zawiR4B3weNfFXop8Z_zKMWuEIntAWaR8fD0Vvzr0_6LfctxvwOMGtVtuMXZk1tNQ
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSgcEG8CBYwEgh5CN7EdxweEyqNq6W5ViVZaqQfjOA5dtE2WfagsP4rfyEw2CRtQ4dRrbEexZzyPzMw3hDxLUy4NF5kf8RgcFM46vpLW-KFMLXMidpnFeufefrRzxD_2RX-F_KxrYTCtspaJpaBOC4v_yDexHVapvuI3o28-do3C6GrdQmPBFntufgYu2-T17nug7_Mw3P5w-G7Hr7oK-FYoMfVVyhMbRDZRRkpEX1cmiWJQo0amQinLlFNcMBXJKJIdmzGXGQPPEJnLgTpl8N5L5DLsiiNWv-w3Dl6AMbwKPiiIo80ABL8fMilLYMBOS_OVDQL-VgNLevDPHM0mUHuNrM3ykZmfmeFwSRdu3yDXKyOWbi247iZZcfktcqVXhelvk-ODE5fPp8Ugp5j1MZvQLuhfrHW2bmpOKRjK9JMb_JiNHT0YF0Dpofk-mNCyYTlNsGsFHeRfgdzUp4aewiJqKvSUO-ToQs77LlnNi9zdJzSJRQYSw1oWG646aZykiiMomnRRCF6CR17VJ6xtBXGOnTaGunR14kgjSTSSRAehZh2PvGwWjBboHudPfYska6YhLHf5oBh_0dUt18K6DAzYAJy0jIPlEwtunHAmzOKMcRN65AUSXKPwgA-zpqqBgO0hDJfeEoyXoUvukfXWTLj0tj1cs4yuhM5E_74iHnnaDONKTKTLXTFbzMFYMos8cm_BYc2WsKYawZA8Ilu819pzeyQfnJSQ5KwsoAYCbNRcuvxZ5xzoRsPG_zv8B__e7hOytnPY6-ru7v7eQ3IVbNoQEzxCtU5Wp-OZewR24zR5XF5WSj5ftHT4BTpnecE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQKxU4IN4EChgJCXpIuxvbiX1cHquytNVKpVIvyHIchwZts6vdrKCc-A_8Q34JM4k32gAV4upHFM_DntHMfEPI8yzjieEiD2MuwUHhrBeqxJowSjLLnJAut1jvfHgU75_w0ak49bk5i1W2-yok2dQ0IEpTWe3NsrxRcRnv9eFKDSOWJDXkHnjsm1KoGHyvzcFgdDxqwwgYVPN4Pn_Z1nmKasT-P-_ltYfp96TJNnJ6nVxdljNz8cVMJmuP0_AmueGtSjpoxOAWueLK22Tr0MfN75CP4zNXXlTToqSYhrFc0AN4ELH42LrKnFOwXOmxK74t546O51Mg_cR8LRa07iBOU2wjQYvyM9Cf_vz-gxp6Dtuo8YAmd8nJ8O2H1_uhb6wQWqFEFaqMp7Yf21SZJEEAemXSWIIlYZJMKGWZcooLBhSN46Rnc-ZyY2AMwckcWBTsHtkop6V7QGgqRQ5KbC2ThqteJtNMccQpS1wcgeEekN0VjbX1qOPY_GKia-9DxhqZopEpuh9p1gvIy3bDrAHcuHzpK2RauwyRsuuB6fyT9oqnhXU52JR98JtyDsaIFNw44UyUy5xxEwXkBbJcoz7Dj1njyxLgeIiMpQeC8TqayAOy3VkJemi70yuh0f4eWGhs4lYbXTIgz9pp3Im5baWbLps1GN5lcUDuNzLWHgnLnBGfKCBJR_o6Z-7OlMVZjRLO6ppmYMDOSk7Xf-sSgu60gvwv4j_8j-8-JVvjN0N98O7o_SNyDUzOCPMvIrVNNqr50j0Gs65Kn3jl_QXqPUOq
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELemTeLjge-PwEBGQoI9pGvjr_ixIMaE2FQJKo0HZDmOQwtpWrWJYHvif-A_5C_B56RRM5gQEq_xWYrPd-c73d3vEHqaplRoyrKQ09gFKJT0QymMDiORGmJZbDMD_c5Hx_xwTN-csJMt9HrdC5PMjAdyzHub7ed53d0A0xPscn-RZrWyx3x_4IxrGBEhPPiei913OGSattHO-Hg0_OB7ixqKBtjnD7s6b5KH7v_dQG-8UOerJ9sU6lV0uSoW-vSrzvONV-rgOpqsz1cXp3zpVWXSM2fnoB__AwNuoGuNJ4uHtejdRFu2uIUuHTW5-tvo42hii9NyPi0wlH5UK_zWPcLQ8GxsqWfYecv4nZ2eVUuLR8u5u-5cf5uusJ9ajhMYXYGnxWd35_jn9x9Y45nbhnUDonIHjQ9evX95GDbDHELDJCtDmdLEDLhJpBYCQO-lTnjsvBctUialIdJKyojkgnPRNxmxmdbuGwCiWefFkLtou5gX9j7CScwyZziMIbGmsp_GSSopYKMJyyMXLASot75OZRqkcxi4kSsf8cRcAdMUME0NIkX6AXrebljUIB8Xk74A-WjJAJ3bf5gvP6lG2RUzNnN-7MDFahl1DlDMqLbM6iiLM0J1FKBnIF0KbIj7MaObVgh3PEDjUkNGqM9g0gDtdiid7pvu8lo-VWN7VgoGx3lHLw7Qk3YZdkI9XWHnVU0DKWXCA3SvFuf2SNBaDZhIARIdQe-cubtSTCcemZz4Pmp3AXtrldj8rQsYutfqzN-Y_-AfaB-iK863jaDQI5K7aLtcVvaR8x_L5HFjG34BHkBoCA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phenytoin+versus+Leviteracetam+for+seizure+prophylaxis+after+brain+injury+-+a+meta+analysis&rft.jtitle=BMC+neurology&rft.au=Zafar%2C+Syed+Nabeel&rft.au=Khan%2C+Abdul+Ahad&rft.au=Ghauri%2C+Asfar+Ayaz&rft.au=Shamim%2C+Muhammad+Shahzad&rft.date=2012-05-29&rft.eissn=1471-2377&rft.volume=12&rft.spage=30&rft_id=info:doi/10.1186%2F1471-2377-12-30&rft_id=info%3Apmid%2F22642837&rft.externalDocID=22642837
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon